| abstract |
FIELD: pharmacology. ^ SUBSTANCE: invention concerns novel compounds of formula (I): , where each of R1, R2, R3 and R4 is independently selected out of hydrogen, hydroxy, and -NHCHO, or R1 and R2 together are selected out of -NHC(=O)CH=CH- and -CH=CHC(=O)NH-; R1 can also be -CH2OH; one of R5 and R6 is -[X-C1-6alkylenyl]n-NR10R11 or C1-6alkylenyl-NR12R13, and the other of R5 and R6 is selected out of hydrogen, C1-4alkoxy and C1-4alkyl, where C1-4alkylis optionally substituted by halogen, where each X is -O-; each of R10, R11, R12 and R13 is independently hydrogen or C1-4alkyl; or R10 and R11 together with nitrogen atom linking them, or R10 together with nitrogen atom linking it and carbon atom from neighbour C1-6alkylenyl form heterocyclic or heteroaryl ring with 5 to 7 atoms in ring and optionally with additional heteroatom selected out of oxygen and nitrogen, where nitrogen atom is optionally substituted by -S(O)2-C1-4alkyl; and n is 1 or 2; and each of R7, R8 and R9 is independently hydrogen; and pharmaceutically acceptable salt or solvate or stereoisomer of claimed compounds. Also invention claims application and pharmaceutical composition based on the compounds and having agonistic effect on 2 adrenergetic receptor. ^ EFFECT: obtaining novel compounds for application in therapy of asthma or chronic obstructive lung disease. ^ 25 cl, 1 tbl, 6 dwg, 17 ex |